13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
87,730 |
14.06.24 15:13:38 |
-0,820 |
-0,93% |
87,730 |
87,770 |
88,320 |
88,550 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
952,800 |
14.06.24 08:05:16 |
-3,200 |
-0,33% |
948,600 |
960,000 |
952,800 |
956,000 |